An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors

Completed · Phase 1

Conditions studied: Non-small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC), Hepatocellular Carcinoma (HCC)

In brief

The purpose of the dose escalation part of this study is to determine the feasibility of using the combination of copanlisib and nivolumab in subjects with advanced solid tumors, and to determine the maximum tolerated dose of copanlisib in combination with nivolumab. The maximum tolerated dose will then be used in Phase 2 (dose expansion) of the study.

Key facts

Study ID

NCT03735628

Run by

Bayer

People needed

16

Starts

2018-10-17

Expected to finish

2022-10-13

Last updated by the study team

2023-10-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants with a histologically confirmed diagnosis of:
• Phase 1b:
• Advanced solid tumors where nivolumab is indicated as per the latest nivolumab Prescribing Information,
• Phase 2:
• Metastatic NSCLC, progressing on or after prior pembrolizumab therapy with or without chemotherapy, irrespective of PD-L1 expression Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations.
• Recurrent or metastatic HNSCC progressing on or after prior pembrolizumab therapy with or without chemotherapy
• HCC progressing after any prior therapy.

You may not qualify if…

• Active, known or suspected autoimmune disease. Participants with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
• Major surgery, open biopsy or significant traumatic injury ≤ 28 days prior to first administration of study intervention. Central line surgery is not considered major surgery
• Symptomatic metastatic brain or meningeal carcinomatosis or tumors unless the participant is > 6 months from definitive therapy (surgery or radiotherapy), has no evidence of tumor growth on an imaging study and is clinically stable with respect to the tumor at the start of study intervention.
• Other malignancy within the last 5 years except for the following, which are permitted:
• curatively treated basal cell/squamous cell skin cancer,
• carcinoma in situ of the cervix,
• superficial transitional cell bladder carcinoma (if BCG [Bacillus Calmette-Guerin] treatment was given, there should be a minimum of 6 months between last dose and enrollment),
• in situ ductal carcinoma of the breast after complete resection,
• participants with localized, resected and/or low-risk prostate cancer may be eligible after discussion with the sponsor's designated medical representative and sponsor's approval.
• Other protocol inclusion/exclusion criteria may apply

Where it is running

• Tower Hematology/Oncology Medical Group — Beverly Hills, California, United States
• Orthopaedic Institute for Children — Los Angeles, California, United States
• Rocky Mountain Cancer Centers / Denver, CO — Denver, Colorado, United States
• Gabrail Cancer Center — Canton, Ohio, United States
• Rhode Island Hospital — Providence, Rhode Island, United States
• Princess Margaret Cancer Centre — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.